Press Releases

The information contained in press releases should be considered accurate only as of the date of the press release. We disclaim any obligation to supplement or update the information in these press releases.

Year

May 1, 2023

Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream

April 20, 2023

Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents

April 18, 2023

Incyte to Present at Upcoming Investor Conferences

April 16, 2023

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

April 11, 2023

Incyte to Report First Quarter Financial Results

March 27, 2023

Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)

March 23, 2023

Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets

March 22, 2023

Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)

March 18, 2023

Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

March 18, 2023

Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Displaying 11 - 20 of 29

Press Releases

For Media Inquiries

For Investor Relations